Page 10 - Marc Jasmin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline May 12, 2021 GMT DARTMOUTH, Nova Scotia (BUSINESS WIRE) May 12, 2021 IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the first quarter ended March 31, 2021. “We remain focused on our commitment to provide effective and well-tolerated immunotherapies for patients with difficult-to-treat cancers. Clinical programs with our lead immunotherapy are progressing as expected, and we are pleased that maveropepimut-S will soon be evaluated in subjects with HR+/HER2- breast cancer, another unmet medical need,” announced Fred Ors, Chief Executive Officer at IMV. “We are reaching another milestone as our second immunother

United statesWayne pisanoJoanne schindlerMandy sheldonMichael kalosEli lillyKyle kuvalankaJames hallMarc jasminYves fradetDelphine davanSociety for immunotherapy of cancerProvidence cancer institute in portlandFred orsChief executive officerAnniversary annual meeting